Dr. Purnanand Sarma serves as the President and Chief Executive Officer of Immunome. He brings nearly 30 years of experience in all aspects of pharmaceutical industry business across multiple R&D platforms, ranging from venture-backed biotechnology start-ups to large cap pharmaceutical companies. He was most recently the President and CEO of Taris Biomedical (acquired by Johnson & Johnson in 2019), which he built over nine years into a leader in therapeutic urology, focused on diseases such as bladder cancer and overactive bladder. Prior to Taris, Sarma was the VP and General Manager of World-wide Drug Delivery Technologies for Cephalon Corporation. Before joining Cephalon, he spent over 10 years in various capacities at Nektar Therapeutics, including VP of Drug Development & Program Management. He started his career at SmithKline Beecham in King of Prussia, PA, after earning his Ph.D. in Pharmaceutics from the University of Minnesota and B. Pharm from Andhra University, Visakhapatnam, India. Sarma also serves as an independent Board member at Vaxess Technologies Inc.
.svg)
